Company Overview and News

 
Rumble Resources calls for trading halt pending assays from the Pilbara

2018-01-15 proactiveinvestors.com.au
Rumble Resources (ASX:RTR) recently wrapped up the first modern drilling program targeting high-grade base metal surface mineralisation at the Braeside Project, located in the Pilbara region of Western Australia.

1
Small miners busy raising $36 million

2017-11-03 businessnews.com.au
It has been a busy few days of raising funds for Perth-based miners Aspire Mines, Rumble Resources and Australian Mines. Aspire Mining today announced a $16.5 million renounceable rights issue to reduce debt and fast-track its Nuurstei Coking Coal project in Northern Mongolia to production in 18 months. Australian Mines requested a halt to trading yesterday pending a release of an announcement of a share placement, thought to raise up to $15 million, to institutional investors in the UK, Hong Kong and Australia.

 
Rumble Resources to reveal joint venture, and answer the ASX

2017-09-28 proactiveinvestors.com.au
Rumble Resources Ltd's (ASX:RTR) shares are in pre-open this afternoon following the ASX granting the company a trading halt.

 
Rumble Resources raising $1M to advance Braeside project

2017-06-27 proactiveinvestors.com.au
Rumble Resources (ASX:RTR) has received binding commitments from professional and sophisticated investors to raise circa $1.07 million via a placement of shares at $0.03 each.

 
Rumble Resources to raise funds after share re-rating

2017-06-21 proactiveinvestors.com.au
Rumble Resources (ASX:RTR) has been granted a trading halt by the ASX, pending details of a capital raising.

 
Rumble Resources shares rise on commencing zinc, lead exploration

2017-05-29 proactiveinvestors.com.au
Rumble Resources’ (ASX:RTR) shares were trading 14% higher intra-day on Monday after commencing exploration at its Braeside zinc-lead project in Western Australia’s East Pilbara region.

 
Rumble Resources gets ready to pounce

2017-03-15 proactiveinvestors.com.au
Rumble Resources (ASX:RTR) has been granted a trading halt by the ASX, with its shares placed in pre-open.

 
Underwritten Rights Issue

2016-05-12 asx.com.au

 
Prospectus

2016-05-12 asx.com.au

 
Appendix 3B

2016-05-12 asx.com.au

 
Half Year Accounts

2016-03-01 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...